Last updated: February 24, 2026
What is the Drug Associated with NDC 00093-4059?
NDC 00093-4059 represents Dextroamphetamine and Amphetamine Tablets, 10 mg. This medication is primarily indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Marketed by several manufacturers under various brand names (e.g., Adderall), this drug is classified as a Schedule II controlled substance.
Market Landscape
Market Size and Demand
- U.S. Market: The ADHD treatment market in the U.S. reached approximately $13 billion in sales in 2022, with stimulants accounting for about 70% of that total.[1]
- Prescription Trends: Estimated at around 35 million prescriptions annually, with a compound annual growth rate (CAGR) of approximately 3-4% over the past five years.[2]
- Key Drivers:
- Rising diagnosis rates, especially among adolescents and adults.
- New formulations and extended-release options.
- Increased awareness and acceptance of medication treatments.
Competitor Landscape
Heavy competition exists among brand-name drugs (e.g., Adderall XR) and generics. The generic market share for amphetamine and dextroamphetamine products is roughly 85-90%, driven by cost sensitivity and insurance coverage.[3] Leading manufacturers include Teva, Sandoz, and Impax.
Regulatory Environment
- The drug remains under Schedule II, restricting prescribing practices and distribution.
- FDA approval for various formulations has increased access, with multiple extended-release and combination products available.
Pricing Analysis
Current Pricing Points
- Brand-name (Adderall IR): Average wholesale price (AWP) per 10 mg tablet: $0.60–$0.85.
- Generic Dextroamphetamine/Amphetamine 10 mg: AWP typically ranges $0.30–$0.50.
- Rebate-adjusted prices are often lower for insurers and pharmacy benefit managers (PBMs).
Price Trends
- Prices for generic amphetamine and dextroamphetamine tablets have declined since 2018 by approximately 15%, reflecting increased competition.
- Extended-release formulations maintain higher prices, with AWP around $1.30–$1.70 per capsule/tablet.
Cost Comparison with Alternatives
| Drug |
Formulation |
Average Wholesale Price (AWP) |
Indications |
Scheduled Status |
| Dextroamphetamine/Amphetamine 10 mg |
Immediate-release tablet |
$0.30–$0.50 |
ADHD, narcolepsy |
Schedule II |
| Methylphenidate (Ritalin, Concerta) |
Immediate and extended-release |
$0.40–$0.80 |
ADHD |
Schedule II |
| Lisdexamfetamine (Vyvanse) |
Extended-release capsule |
$2.00–$2.50 |
ADHD, binge eating |
Schedule II |
Price Projection
Short-term (Next 12 Months)
- Generic downward pressure expected to continue due to intensified competition.
- Prescription rates stable, with potential modest increases driven by diagnostic growth.
Projected Price Range (Awareness to 2024):
- Average wholesale price: $0.25–$0.45 per 10 mg generic tablet.
- Wholesale acquisition cost (WAC): Expected to stabilize or decline slightly (<5%).
Long-term (Next 3–5 Years)
- Patent expirations for branded products (e.g., Adderall XR) planned, increasing generic market penetration.
- Price erosion likely, with estimates suggesting 10-15% reduction in wholesale prices for generics over this period.
- Potential for price stabilization if new formulations or biosimilars emerge, but no biosimilar pathway exists for this class.
Factors Impacting Pricing
- Changes in prescribing regulations or scheduling policies.
- Supply chain disruptions, especially considering ongoing concerns post-pandemic.
- Introduction of lower-cost generics or new formulations with patent protections.
- Insurance and PBM pricing strategies.
Key Takeaways
- The drug corresponding to NDC 00093-4059 is extensively used in ADHD and narcolepsy management, with a sizable and growing market.
- The market is highly competitive, dominated by generic versions, which drives prices downward.
- Short-term prices are expected to remain stable or decline marginally, with a possible 10-15% decrease over the next 3–5 years due to patent expirations and increased generic competition.
- Formulation type influences pricing: immediate-release generics remain the most affordable, while extended-release formulations maintain higher prices.
- Regulatory factors and health policy changes can significantly impact future pricing and supply dynamics.
References
[1] IQVIA. (2022). National Prescription Audit.
[2] CDC. (2021). Adult and Pediatric ADHD Prevalence.
[3] SSR Health. (2022). Pharmaceutical Pricing Trends.
[4] FDA. (2023). Drug Approvals and Regulatory Actions.
FAQs
1. How does the availability of generics affect the price of NDC 00093-4059?
Generic availability typically reduces prices through increased competition, leading to a decline of roughly 15%–20% since 2018.
2. Are there upcoming patent expirations that could influence prices?
Yes, branded formulations like Adderall XR are scheduled for patent expiry in 2024–2025, likely increasing generic market share and lowering prices.
3. Will new formulations impact prices?
Extended-release and combination versions often carry higher prices, but increased competition may lead to discounts or better pricing options.
4. How does insurance coverage influence market prices?
Insurance and PBMs negotiate rebates, which can reduce out-of-pocket costs for consumers but may not reflect actual wholesale prices.
5. What factors could cause prices to increase in the future?
Regulatory changes, supply shortages, or new patent protections could disrupt existing pricing trends.
[1] IQVIA. (2022). National Prescription Audit.
[2] CDC. (2021). Adult and Pediatric ADHD Prevalence.
[3] SSR Health. (2022). Pharmaceutical Pricing Trends.
[4] FDA. (2023). Drug Approvals and Regulatory Actions.
